Enara Bio Ltd. is staking a claim to having validated the first in a new class of tumor antigens derived from unannotated regions of the dark genome, describing its findings in talks and posters being presented at the Society of Immunotherapy in Cancer (SITC) meeting in National Harbor, Md., Nov. 5-9, 2025.
There is increasing interest in developing precision immunotherapies that target tumors but with minimal impact on healthy tissues. IL-12 is a potent immunostimulatory cytokine that has shown effective antitumoral activity in the preclinical setting, but its systemic delivery may be accompanied by off-target effects.
Nectin-4 antibody-drug conjugate (ADC) and checkpoint inhibitor combinations have represented a great advancement in the treatment of bladder cancer, but relapse and treatment-related toxicities underscore the need for new therapeutic strategies.
Researchers from Anaveon AG and affiliated organizations presented the discovery and preclinical characterization of ANV-700, a novel proximity-activated cytokine (PAC) compound designed to selectively deliver IL-21 to PD-1-expressing cells for the treatment of cancer.
AGEN-1721 was designed as an Fc-enhanced bifunctional antibody to selectively target FAP and neutralize TGF-β via an optimized TGF-βR2 TRAP moiety fused to an engineered Fc region, with the aim of maximizing effector functions.
Researchers from SL Bigen Inc. and collaborators presented the preclinical characterization of BM-205, a novel entity of engineered MSCs designed to exert antitumor functions.
Compared to normal tissues, where the expression of ULBP2/5/6 protein is restricted, in non-small-cell lung cancer (NSCLC), head and neck cancer and squamous urothelial carcinoma, the levels of ULBP2/5/6 remain high even following relapse from standard-of-care therapies and is retained in metastatic lesions. Besides, these squamous cell cancers showed a high proportion of CD2+ tumor-infiltrating lymphocytes compared to other co-stimulatory receptors.
Researchers from Astrazeneca plc presented the discovery and preclinical characterization of AZD-9793, a novel CD8-guided T-cell engager (TCE) being developed for the treatment of hepatocellular carcinoma (HCC).
Researchers from Caedo Oncology AS presented the discovery and preclinical characterization of CO-005, a novel anti-CD47 fusion protein being developed for the treatment of lymphoma.
Bright Biologics LLC reported the discovery and preclinical evaluation of BB-203, an anti-PD-L1/anti-VEGF bispecific antibody (Ab) being developed for the treatment of cancer.
RSS
